SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
about
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
SYD985, a Novel Duocarmycin-Ba ...... coma with HER2/Neu Expression.
@en
SYD985, a Novel Duocarmycin-Ba ...... coma with HER2/Neu Expression.
@nl
type
label
SYD985, a Novel Duocarmycin-Ba ...... coma with HER2/Neu Expression.
@en
SYD985, a Novel Duocarmycin-Ba ...... coma with HER2/Neu Expression.
@nl
prefLabel
SYD985, a Novel Duocarmycin-Ba ...... coma with HER2/Neu Expression.
@en
SYD985, a Novel Duocarmycin-Ba ...... coma with HER2/Neu Expression.
@nl
P2093
P2860
P1476
SYD985, a Novel Duocarmycin-Ba ...... coma with HER2/Neu Expression.
@en
P2093
Alessandro D Santin
Alice Masserdotti
Babak Litkouhi
Dan-Arin Silasi
Elena Bonazzoli
Elena Ratner
Federica Predolini
Francesca Pettinella
Gary Altwerger
Gulden Menderes
P2860
P304
P356
10.1158/1078-0432.CCR-16-2862
P407
P577
2017-07-05T00:00:00Z